Metformin Improves the Prerequisites for FGF21 Signaling in Patients With Type 2 Diabetes
Authors' conclusion
Our findings suggest that metformin suppresses the circulating FAP activity and upregulates the expression of FGFR1c and β-klotho for increased FGF21 signaling in adipose tissue, thus improving peripheral FGF21 sensitivity.
Study context
- Population
- Patients with T2D; plus BMI- and age-matched healthy individualsT2D
- Participants
- 24 patients
- Comparison
- Metformin vs placebo in T2D
- Healthy controlsn = 12
Methodological detailsplacebo-controlled, BMI- and age-matched healthy control group on metformin
- Placebo-controlled
- BMI- and age-matched healthy control group on metformin
Primary result
As reported in the abstract
FGF21 signaling pathway · 12 weeks
- Circulating fibroblast activation protein (FAP) activity decreased after metformin vs placebo
- FGF21 levels were unchanged
- Metformin increased gene and protein expression of β-klotho, FGFR1c and pFGFR1c in adipose tissue
- FGF21 mRNA expression increased in muscle after metformin; FGF21 protein, but not mRNA, observed in adipose tissue
- Metformin vs Placebo: P = 0.006
Original publication
Metformin Improves the Prerequisites for FGF21 Signaling in Patients With Type 2 Diabetes. J Clin Endocrinol Metab. Published 30 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →